GILEAD SCIENCES INC (GILD) Stock News
NASDAQ:GILD - Nasdaq - US3755581036 - Common Stock - Currency: USD
GILD Latest News, Press Relases and Analysis
Top S&P500 movers in Wednesday's session
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.
These S&P500 stocks have an unusual volume in today's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.
Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup
Plus, Trump threatens tariffs on pharmaceuticals, and Eli Lilly sets its eyes on preventing Alzheimer's
Mentions: LLY
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Gilead Sciences to Present at Upcoming Investor Conferences
The FDA could approve a new twice-yearly HIV prevention treatment this year
Gilead said the FDA is reviewing its experimental twice-yearly injectable drug designed to prevent HIV
Big Pharma CEOs Visit the White House
This week the CEOs of big pharma companies including Pfizer, Merck and Gilead will meet with President Trump to discuss potential reforms in the sector, but pharmacy benefit managers like CVS were left out of the discussions. Prem Shah, the executive Vice President and Group President of CVS Health joined Bloomberg Open Interest to talk about where he sees US healthcare under Trump's second term. (Source: Bloomberg)
Mentions: PFE
Arcus Biosciences price target lowered to $18 from $20 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Arcus Biosciences (RCUS) to $18 from $20 and keeps a Buy rating on the shares after the compa...
Lyft downgraded, Snowflake upgraded: Wall Street's top analyst calls
Lyft downgraded, Snowflake upgraded: Wall Street's top analyst calls
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect.
S&P 500 ends down as hot US inflation data hints at fewer rate cuts
Nvidia and Amazon dipped, with the two AI computing heavyweights weighing on the S&P 500.
Why Gilead Sciences (GILD) Stock Is Trading Up Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue, EPS, and adjusted operating income estimates. Revenue grew 6%, driven by a 16% increase in HIV product sales and supported by strength in oncology and liver disease products. The momentum is expected to continue into the next year, as full-year EPS guidance surpassed Wall Street estimates, while sales gu
These S&P500 stocks are moving in today's session
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Discover the top S&P500 movers in Wednesday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Wednesday's pre-market session.